Why the study?
What are the cardiovascular complications and mechanisms of damage associated with molecular target therapies in oncology?
What are the cardiovascular complications and mechanisms of damage associated with molecular target therapies in oncology?
This review highlights the critical need for awareness and monitoring of cardiotoxicity in patients receiving molecular targeted therapies for cancer.
Clinicians should monitor for cardiotoxicity with molecular therapies; Level 5 data leaves open the need for prospective cardio-oncology trials.
Since the introduction of new drugs, (commonly referred to as ‘Molecular Target Therapies’), into oncological clinical practice both the number of objective indicators/endpoints of achieved treatment response and cancer survival duration have increased. Nevertheless, the risk of cardiovascular complications has also risen. Optimistic reports on the relatively low cardiotoxicity of these drugs have been verified through experience. Routine clinical practice has witnessed growing numbers of new drug groups that have different molecular target points and also a varied cardiotoxicity.This paper presents the most important cardiovascular complications associated with the use of molecularly targeted drugs and includes their mechanisms of development.
No takes yet. Share an insight, caveat, or question.
Jagielska et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: